Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.
about
ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistanceCrizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancerIntegrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancerAutophagy is not uniformly cytoprotective: a personalized medicine approach for autophagy inhibition as a therapeutic strategy in non-small cell lung cancer.The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.Does ALK-rearrangement predict favorable response to the therapy of bevacizumab plus pemetrexed in advanced non-small-cell lung cancer? Case report and literature review.
P2860
Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Novel targeted therapies for r ...... cancer: ceritinib and beyond.
@en
type
label
Novel targeted therapies for r ...... cancer: ceritinib and beyond.
@en
prefLabel
Novel targeted therapies for r ...... cancer: ceritinib and beyond.
@en
P2093
P2860
P356
P1476
Novel targeted therapies for r ...... cancer: ceritinib and beyond.
@en
P2093
Ajit Paintal
Cesar A Perez
Goetz H Kloecker
Zeyad Kanaan
P2860
P304
P356
10.2147/OTT.S67262
P407
P577
2015-04-20T00:00:00Z